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INTRODUCTION
Avian leukosis is a disease of the birds produced
by the virus of the leukosis/sarcoma group belonging
to alpharetrovirus genus of the Retroviridae family (1).
The ALVs that infect chickens are divided in six
subgroups: A, B, C, D, E and J, which are differentiated
for the antigen of the viral cover for seroneutralisation
(2). The last member discovered, J subgroup, emerged
at the end of the 80s (3) and it has continued in the
last years with special characteristics which have
caused its spread all over the world, causing great
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ABSTRACT: Avian leukosis viruses (ALV) provoke a variety of trasmissible bening and malign tumoral
diseases affecting birds. Chickens are affected by six subgroups of ALV designs A, B, C, D, E and J of
more recent world dissemination. These viruses are potential contaminants of live vaccines used in
poultry. In order to research the presence of DNA from ALVs as contaminants of viral commercial
vaccines to be used in poultry, different Marek´s disease vaccines were screened by a reported polymerase
chain reaction (PCR) assay designed to detect all subgroups of ALVs. DNA samples extracted from
seven vaccines were submitted to PCR using primers for a conserved region of env gene of HPRS-103.
ALV sequences were detected in seven samples (100%). The methodology employed proved to be useful
for the detection of ALVs as contaminants of imported Marek´s disease vaccines. These data suggest a
high occurrence of ALVs in commercial vaccines intended for poultry disease prevention.
(Key words: avian leukosis virus (ALV); polymerase chain reaction (PCR); vaccine; contamination; poultry)
REACCIÓN EN CADENA DE LA POLIMERASA PARA LA DETECCIÓN DE VIRUS DNA
DE LEUCOSIS AVIAR  EN VACUNAS USADAS EN LA AVICULTURA
RESUMEN: Los virus de la leucosis aviar (ALV) provocan una variedad de enfermedades tumorales
benignas y malignas transmisibles que afectan a las aves. Los pollos son afectados por seis subgrupos
de ALV designados A, B, C, D, E y J de más reciente  diseminación mundial. Estos virus son, además,
potenciales contaminantes de vacunas vivas usadas en la avicultura. Para investigar la presencia de
ADN de ALV como contaminante de vacunas virales comerciales usadas en la avicultura, monitoreamos
diferentes vacunas de la enfermedad de Marek en un ensayo reportado por Reacción de la Cadena de
la Polimerasa (PCR) diseñado para detectar todos los subgrupos del ALV. Las muestras de ADN extraídas
de siete vacunas fueron evaluadas por PCR utilizando cebadores para una región conservada  del gen
de la envoltura (env) de HPRS-103. Las secuencias del ALV fueron detectadas en las siete muestras
(100%). La metodología empleada resultó útil para la detección de ALV como contaminante de vacunas
de Marek importadas. Nuestros datos sugieren una elevada presencia de ALV en vacunas comerciales
destinadas a la prevención de enfermedad en la avicultura.
(Palabras clave: virus de la leucosis aviar (ALV); reacción en cadena de la polimerasa (PCR); vacuna;
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losses and it attributes a part of growth decrease in
the world poultry (2,4).
These viruses are potential contaminants of live
vaccines used in poultry which could produce
infections in chicken populations of specific pathogens
free (SPF) with the contamination of a fertile eggs
proportion due to ovotransmission. The viral
contamination results in the commitment of the quality
of the seeds and vaccines elaborated starting from
embryos of chicken or their cellular cultivations. Birds
containing ALV vaccinated at very early age with
biological products could develop tumors, present
immunosupression and decrease humilities; thus the
evaluation of the absence of contaminants from the
master seed of production until the final product is of
great importance.
The viral isolation in cell cultures as routine and
the revealed of the viral multiplication by complement
fixation test (COFAL) or ELISA to detect the presence
of specific group of antigens (5,6) have been methods
employed for the detection of contamination with ALV.
The PCR based technology have been described for
the detection of different viruses in vaccine
preparations such as Newcastle disease virus (7),
infectious bronchitis virus (8) and canine parvovirus
(9). Fadly et al. (10,11) revealed contamination of
vaccines with ALVs, specifically in two Marek´s
vaccines, which confirms that these agents are
potential contaminants of viral vaccines applied in
poultry. This assay has meant a considerable advance
due to a higher sensitivity and specificity upon
differentiating the subgroups compared with ELISA. It
is quicker than the viral isolation, which requires until
10 days and it needs detection by ELISA for the
identification result (12).
The purpose of the present study was to research
the possible presence of ALV DNA as contaminant of
Marek´s disease vaccines intended to be used in
poultry by ALV specific PCR assay (13).
For the PCR assay positive control, a strain of the
ALV-J, the HPRS-103 donated by Dr. Venugopal of
the Animal Health Institute, Compton England, was
used. Seven Marek´s disease vaccines from several
commercial companies were evaluated. Primary
cultures of turkey´s embryo fibroblast were prepared
as referred by  Payne et al. (14).
To obtain cells infected with AL-J virus in order to
be used as positive control in the PCR assay, cellular
cultures of turkey´s embryo fibroblast of 24 hours were
inoculated, as described by Fadly and Witter (5).
Such cultures were placed in incubation at 37°C
and 0.5 % of CO2 and the medium changed at 24
hours, 7 days post-inoculation (PI). Observation was
carried out until 12 post-inoculation,  and supernant
samples of the cultures at 7 days and cells and
supernant were obtained at 12 days in order to evaluate
viral multiplication.
The presence of ALV in infected cells was
confirmed by an enzyme–linked immunosorbent assay
(IDEXX, Laboratories, Inc.) (15).
DNA extraction from the cells infected with HPRS-
103 strain was carried out according to the method
described by Maniatis et al. (16). Extracted DNA was
resuspended in 100 uL of TE buffer 1X and it was
frozen to -20ºC until its evaluation.
DNA extraction of vaccine samples was carried out
resuspending the vaccine bulb in 0.5 mL of saline
sterile solution (500 dose).
For the amplification of all ALV subgroup, the
oligonucleotides (H5/AJ1) were selected (Venugopal,
personnal communication) (Table 1).
The mixtures for PCR reaction in a total volume of
20 uL are as follows: 1X buffer (Promega) (50 mM
KCl, 10 mM Tris-HCl pH 9.0 y 0.1% Triton® X-100),
dNTP (250 uM), magnesium chloride solution (2.0 mM,
Promega), 0.5 uM of each primer, 0.125 U/uL of the
Taq polymerase enzyme (Promega). DNA yield and
purity were determined by spectrophotometry
(GenesysTM 6, USA).
As a negative control for PCR assay, DNA template
was replaced by the same amount of nuclease free
water (Promega, Madison, WI, USA). Amplifications
TABLE 1. Primers used in PCR reactions./ Cebadores empleados en las reacciones de PCR 
*From the available HPRS-103 sequences of ALV (17). 
 
Specificity Primer Sequences (5’-3’) Positions * 
Avian leukosis H5 GGATGAGGTGACTAAGAAAG 5258-5278 
Avian  leukosis AJ1 ATGAACGGCCCATTCYCCTATTCC 7036-7060 
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were performed in MJ-ResearchTM thermocycler. The
temperature profile involved a first step at 94ºC for 3
min., 30 cycles of 1 min at 94ºC, 1 min. at 54ºC and 1
min. at 74ºC. A final extension time was of 10 min. at
74ºC.
A 10 uL aliquot of each PCR product was visualized
by agarose gel electrophoresis (0.8 %), containing 0.8
mg/ml ethidium bromide solution. Gels were
electrophoresed for 30 min at 100 V in buffer TBE
0.5X [Tris-Borato (Tris 50mM, borate acid 50 mM] and
EDTA 10 mM, pH 8.4). For the determination of the
size of PCR products, molecular weight markers 1 Kb
DNA ladder (Promega) with a size range from 100 to
10000 bp were included. Bands were visualized at a
wave length of 312 nm and photographed.
The use of turkey’s embryo fibroblast allowed to
obtain virus stock of high titer according to Payne et
al. (14).
Bands of expected size (1800 pb) were obtained
in all Marek´s disease vaccines evaluated (Fig.1).
FIGURE 1. PCR for the detection of ALVs in vaccine samples.
Lanes: M- 1kb DNA ladder (Promega); 1- Negative control (nu-
clease free water, Promega); 2- Positive control (HPRS-103); 3-
9: samples of commercial vaccines./  PCR para la detección de
ALV en muestras de vacunas. Líneas M- Marcador de 1kb
(Promega); 1- Control negativo (agua libre de nucleasas,
Promega); 2- Control positivo (HPRS-103); 3-9 Muestra de
vacunas comerciales.
These results coincide with reports of Fadly et al.
(10,11) and Silva (18) who revealed the presence of
ALVs in vaccines, specifically ALV-A in a commercial
Marek´s disease vaccine and they alerted about the
need of using sensitive and specific methods for the
detection of those viruses as contaminants of vaccines.
Also, later Zavala and Cheng (19) carried out the
identification by PCR and the characterization of ALVs
in several commercial Marek´s disease vaccines and
evaluated their effect in experimentally vaccinated
chickens. These authors recommended the
employment of these methods as complementary
procedures for the detection of these viruses in the
commercial vaccines destined to poultry.
Although at present, subgroups A, B (19) and E
(20) of the ALVs were only identified as contaminant
of vaccines, given the wide spread of the ALV-J also
infecting leghorn chickens and turkeys (21,22,23), it
is very important to have more sensitive and specific
methods in order to reveal their presence in vaccinal
products as well as in imported birds in order to avoid
the dissemination of the disease in the country.
In our work, DNA extraction was carried out directly
from vaccine bulb, it is very important because it
reduces  time to get the results. Authors like Fadly et
al. (24) reveled the presence of endogenous and
exogenous viruses afterwards cellular cultures from a
commercial Marek´s disease by PCR.
The results obtained showed that the methodology
described is a valuable tool for the detection of leukosis
viruses in veterinary vaccines and could become a
practical alternative for the current in vivo test for vaccine
control imported or produced in our country. Our data
suggest a high occurrence of ALVs in commercial viral
vaccines intended for poultry disease prevention.
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